

In the Claims

Please cancel claim 16 without prejudice. Please amend claims 1, 2, 5, 6, 12, 13, 15, 17-21, 24, 34, 43, and 56 as shown below. Applicants have submitted a new complete claim set including marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1. (Currently Amended) A method for treating or preventing cancer, the method comprising:
administering to a subject having or at risk of developing cancer ~~an effective amount (a)~~
~~an immunostimulatory nucleic acid in an effective amount~~ to upregulate CD20 expression ~~of a~~
~~nucleic acid~~, and (b) an anti-CD20 antibody.
2. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is ~~an immunostimulatory~~ a CpG nucleic acid having an unmethylated CpG motif.
- 3.4. (Withdrawn)
5. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is bacterial DNA.
6. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is eukaryotic DNA.
7. (Original) The method of claim 1, wherein the cancer is B-cell lymphoma associated with low levels of CD20 expression.
8. (Original) The method of claim 7, wherein the B-cell lymphoma is B-cell chronic lymphocytic leukemia (B-CLL).

9. (Original) The method of claim 7, wherein the B-cell lymphoma is a marginal zone lymphoma.
10. (Original) The method of claim 1, wherein the anti-CD20 antibody is C2B8.
11. (Original) The method of claim 1, wherein the anti-CD20 antibody is Rituximab.
12. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid does not hybridize with genomic DNA or RNA under stringent conditions.
13. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid has a modified backbone.
14. (Original) The method of claim 13, wherein the modified backbone is a phosphate backbone modification.
15. (Currently Amended) The method of claim 13, wherein the modified backbone is an amino acid a peptide-modified oligonucleotide backbone.
16. (Cancelled)
17. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is 8 to 40 nucleotides in length.
18. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is isolated.
19. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid is a synthetic nucleic acid.

20. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid and the anti-CD20 antibody are administered together.

21. (Currently Amended) The method of claim 1, wherein the immunostimulatory nucleic acid and the anti-CD20 antibody are administered separately.

22. (Withdrawn)

23. (Cancelled)

24. (Currently Amended) A method for treating or preventing cancer, the method comprising:

administering to a subject having or at risk of developing cancer an immunostimulatory nucleic acid in an effective amount to induce expression of a surface antigen on a cancer cell surface, ~~of a nucleic acid, wherein said surface antigen is chosen from a CD22 antigen and a CD19 antigen, and~~

administering to the subject an antibody ~~selected chosen~~ from the group consisting of an anti-CD22 antibody and an anti-CD19 antibody.

25.-33. (Cancelled)

34. (Currently Amended) A method for treating lymphoma, the method comprising:
isolating a B cell from a subject having lymphoma,
identifying a surface antigen which is not expressed or which is expressed on the surface of the B cell in an amount lower than that of a ~~control~~ normal B cell, and

administering to the subject ~~(a) an antibody specific for the identified surface antigen and an immunostimulatory nucleic acid in order to treat the cancer, wherein the immunostimulatory nucleic acid is administered~~ in an effective amount to upregulate expression of the surface antigen on the cancer cell surface and (b) an antibody specific for the surface antigen.

35.-42. (Cancelled)

43. (Currently Amended) A method for treating a lymphoma resistant to antibody therapy, the method comprising:

administering to a subject having a lymphoma resistant to therapy with an antibody specific for a surface antigen, an antibody specific for the surface antigen ~~to which the lymphoma is resistant and an immunostimulatory nucleic acid in order to treat the lymphoma,~~ wherein the nucleic acid is administered in an effective amount to upregulate expression of the surface antigen on the lymphoma cell surface.

44.-55. (Cancelled)

56. (Currently Amended) A method for treating cancer in a human, the method comprising:

administering to a human having a cancer with cells expressing a cell surface antigen an immunostimulatory nucleic acid and an antibody of IgG1 isotype, which antibody binds to a the cell surface antigen of a cancer cell and, wherein the nucleic acid and the antibody are administered in an effective amount for killing the cancer cell cells expressing the cell surface antigen.

57.-75. (Cancelled)

76. (Withdrawn)

77. (Cancelled)